52350 PKM2 mediates anti-tumor immunity and T cell dysfunction
ABSTRACT IMPACT: T cell dysfunction is a dominant suppressor of anti-tumor immunity, reducing immunotherapeutic efficacy and benefit to patients; our work will identify novel mediators of this process for both therapeutic potential and underlying mechanism, allowing for both potential immediate clin...
Main Authors: | Geoffrey Markowitz, Yi Ban, Michael Crowley, Diamile Tavarez, Stephen T.C. Wong, Kenneth Chang, Andrea Schietinger, Nasser Altorki, Vivek Mittal |
---|---|
Format: | Article |
Language: | English |
Published: |
Cambridge University Press
2021-03-01
|
Series: | Journal of Clinical and Translational Science |
Online Access: | https://www.cambridge.org/core/product/identifier/S2059866121006300/type/journal_article |
Similar Items
-
Tumor-intrinsic IRE1α signaling controls protective immunity in lung cancer
by: Michael J. P. Crowley, et al.
Published: (2023-01-01) -
The expression of PKM1 and PKM2 in developing, benign, and cancerous prostatic tissues
by: Lin Li, et al.
Published: (2024-04-01) -
Metabolic Alterations Caused by Simultaneous Loss of HK2 and PKM2 Leads to Photoreceptor Dysfunction and Degeneration
by: Eric Weh, et al.
Published: (2023-08-01) -
Simultaneous suppression of PKM2 and PHGDH elicits synergistic anti-cancer effect in NSCLC
by: Kaixuan Wang, et al.
Published: (2023-05-01) -
Sistem penilaian kebergunaan PKM (SPKpkm)
by: Sahari @ Ashaari, Noraidah, et al.
Published: (2007)